- World rank, all time
- #29,333 of 42,892
- Rank in Canada
- #628 of 896
- Research works
- 188 ▲ 51% vs 2013–17
- Citations
- 3.5k 18.7 per fractional work
- Top-10% rate
- 16.4% record average 16.5%
- Open access
- 58% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 6.8×. Every wedge is a field page.
- Immunology and Microbiology 6.8×
- Pharmacology, Toxicology and Pharmaceutics 3.2×
- Medicine 2.8×
- Biochemistry, Genetics and Molecular Biology 2.3×
- Economics, Econometrics and Finance 2.2×
- Mathematics 1.3×
- Health Professions 1.2×
- Psychology 0.7×
- Chemistry 0.4×
- Social Sciences 0.3×
- Engineering 0.3×
- Environmental Science 0.3×
- Decision Sciences 0.2×
- Agricultural and Biological Sciences 0.1×
- Computer Science 0.1×
- Neuroscience 0.1×
- Business, Management and Accounting 0.1×
- Materials Science 0.1×
Which keywords describe research at Pfizer (Canada)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Epidemiology, Antimicrobial Resistance, Vaccine Development, Disease Burden, Human Metapneumovirus, Respiratory Syncytial Virus, Antibiotic Resistance and Clinical Practice Guidelines.
- Spondyloarthritis
- Inflammatory Bowel Disease
- Critically Ill Patients
- Antimicrobial Stewardship
- Hemophilia
- Disease-Modifying Antirheumatic Drugs
- Safety
- Prophylaxis
- Health Utility Measures
- Cardiovascular Risk
- Drug Resistance
- Gene Therapy
- ESKAPE Pathogens
- Public Health
- Pneumococcal Conjugate Vaccine
- Respiratory Infections
- Clinical Practice Guidelines
- Respiratory Syncytial Virus
- Disease Burden
- Antimicrobial Resistance
- Epidemiology
- Vaccine Development
- Human Metapneumovirus
- Antibiotic Resistance
- Inflammation
- Community-Acquired Pneumonia
- Pathogenesis
- Quality of Life
- Multidrug-Resistant Bacteria
- Autoantibodies
- Infectious Diseases
- Cost-effectiveness Analysis
- Inhibitors
- Rheumatoid Arthritis
- Biological Therapy
- Factor VIII
- Antibiotic Pharmacokinetics
- Bacterial Infections
- Global Health
- Ankylosing Spondylitis
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology16▲ 6.8×35 topics
- Antimicrobial Resistance5▲ 45×4 topics
- Vaccine Development5▲ 31×3 topics
- Disease Burden4▲ 106×2 topics
- Human Metapneumovirus4▲ 166×1 topic
- Respiratory Syncytial Virus4▲ 166×1 topic
- Antibiotic Resistance4▲ 19×5 topics
- Clinical Practice Guidelines4▲ 11×3 topics
- Inflammation3▲ 2.8×10 topics
- Respiratory Infections3▲ 47×2 topics
- Community-Acquired Pneumonia3▲ 161×1 topic
- Pneumococcal Conjugate Vaccine3▲ 161×1 topic
- Pathogenesis3▲ 10×10 topics
- Public Health3▲ 3.0×7 topics
- Quality of Life2▲ 2.9×5 topics
- ESKAPE Pathogens2▲ 68×1 topic
- Multidrug-Resistant Bacteria2▲ 68×1 topic
- Gene Therapy2▲ 19×4 topics
- Autoantibodies2▲ 14×4 topics
- Drug Resistance2▲ 12×2 topics
- Infectious Diseases2▲ 9.6×4 topics
- Cardiovascular Risk2▲ 9.7×2 topics
- Cost-effectiveness Analysis2▲ 35×1 topic
- Health Utility Measures2▲ 35×1 topic
- Inhibitors2▲ 71×2 topics
- Prophylaxis2▲ 23×2 topics
- Rheumatoid Arthritis2▲ 32×3 topics
- Safety2▲ 127×2 topics
- Biological Therapy2▲ 52×1 topic
- Disease-Modifying Antirheumatic Drugs2▲ 59×1 topic
- Factor VIII2▲ 201×1 topic
- Hemophilia2▲ 201×1 topic
- Antibiotic Pharmacokinetics2▲ 88×1 topic
- Antimicrobial Stewardship2▲ 62×1 topic
- Bacterial Infections2▲ 62×1 topic
- Critically Ill Patients2▲ 88×1 topic
- Global Health2▲ 18×2 topics
- Inflammatory Bowel Disease2▲ 24×4 topics
- Ankylosing Spondylitis2▲ 90×1 topic
- Spondyloarthritis2▲ 90×1 topic
Which research topics does Pfizer (Canada) publish most on?
By volume in 2022–2025: Respiratory viral infections research, Pneumonia and Respiratory Infections, Antibiotic Resistance in Bacteria and Health Systems, Economic Evaluations, Quality of Life.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Respiratory viral infections research Epidemiology 4 works
- 2 Pneumonia and Respiratory Infections Epidemiology 3 works
- 3 Antibiotic Resistance in Bacteria Molecular Medicine 2 works
- 4 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 2 works
- 5 Rheumatoid Arthritis Research and Therapies Rheumatology 2 works
- 6 Hemophilia Treatment and Research Hematology 2 works
- 7 Antibiotic Use and Resistance Applied Microbiology and Biotechnology 2 works
- 8 Antibiotics Pharmacokinetics and Efficacy Pharmacology 2 works
- 9 Spondyloarthritis Studies and Treatments Rheumatology 2 works
- 10 Inflammatory Bowel Disease Genetics 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Pfizer (Canada)'s research output changed?
Output in 2018–2022 was 51% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Kirkland
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.